Read the latest from Baszucki Group and its partners.
September 12, 2022 — The Baszucki, Dauten, and Brin families joined with the Milken Institute to launch BD²: Breakthrough Discoveries for thriving with Bipolar Disorder. As the largest private investment focused on the study of bipolar disorder, BD² provides an unprecedented opportunity to identify breakthroughs in scientific understanding that create new interventions so that everyone with bipolar disorder can thrive.
September 6, 2022 — The FDA has approved the SAINT Neuromodulation System for the treatment of major depressive disorder in adults who have not seen improvement using antidepressant medications. The Baszuckis are proud to have partnered with Nolan Williams and Magnus Medical to make this timely and personalized treatment accessible to patients with debilitating conditions.
August 17, 2022 — The Baszucki Brain Research Fund and the Milken Institute’s Center for Strategic Philanthropy today announced the launch of the Metabolic Mind Award Program, recognizing champions working at the intersection of metabolism and mental health in the emerging field of metabolic psychiatry. This year’s award focus will be on Ketogenic Metabolic Therapy for mental health.
July 21, 2022 — The Baszuckis are showing how philanthropy, even one organization, can potentially make a big impact on an underfunded field of research. But they can’t solve this on their own — by getting this new research rolling, their most significant role could be producing promising results that attract new funders to the space.